Remdesivir most promising COVID-19 drug, say researchers
Posted: 27 March 2020 | Hannah Balfour (Drug Target Review) | 2 comments
A review of potential COVID-19 therapeutics revealed that the most effective are likely to be those directly targeting SARS-CoV-2, such as remdesivir and tilarone.
The authors of a review and article of all the potential therapeutics and vaccines for COVID-19 revealed that they believe the most effective therapeutic drugs will directly target the SARS-CoV-2 virus that causes COVID-19.
With regular news updates and feature articles, our COVID-19 hub has everything you need to keep up to date with R&D during the pandemic. Click below to visit:
Other approaches listed in their review and article published in Antimicrobial Agents and Chemotherapy include blocking SARS-CoV-2 from entering cells, disrupting viral replication, antivirals, vaccines and suppressing overactive immune response.
According to the authors, SARS-CoV-2 is easily transmissible because Spike (S) proteins on the surface of the virus bind exceptionally efficiently to the angiotensin-converting enzyme 2 (ACE2) on the surfaces of human cells. One clinical study is already underway, testing if recombinant ACE2 can act as a decoy, binding the S proteins and preventing SARS-CoV-2 infecting cells in patients with severe COVID-19.
Drug Target Review has just announced the launch of its NEW and EXCLUSIVE report examining the evolution of AI and informatics in drug discovery and development.
In this 63 page in-depth report, experts and researchers explore the key benefits of AI and informatics processes, reveal where the challenges lie for the implementation of AI and how they see the use of these technologies streamlining workflows in the future.
Also featured are exclusive interviews with leading scientists from AstraZeneca, Auransa, PolarisQB and Chalmers University of Technology.
The article suggests the most promising COVID-19 antiviral is remdesivir, which gets incorporated into viral RNA and prevents it being synthesised, halting viral replication. Remdesivir inhibited SARS-CoV-2 replication in laboratory studies and was tested in one patient with COVID-19 in US. The patient’s symptoms improved following intravenous remdesivir administration; however, more clinical data is required before the drug can be approved for use.
Tilarone is a broad-spectrum antiviral that may also be active against SARS-CoV-2. The synthetic small molecule is used in some countries, including Russia and neighbours, to treat several viruses, including acute respiratory viral infection, influenza and hepatitis. Other studies suggest tilarone may be active against Middle Eastern Respiratory Syndrome (MERS-CoV); however, the studies do not meet US Food and Drug Administration (FDA) standards for safety.
A further treatment option currently being explored, according to the authors, is the transfusion of blood from a recovered COVID-19 patient into someone with an active viral infection. This has primarily been used for patients in critical condition as it has a lack of high quality randomised clinical trial data to back up its efficacy. Several clinical trials investigating its effectiveness and safety against COVID-19 are now in progress.
The review cited more than 15 vaccine candidates being developed globally, with various approaches to their design. The authors suggest the expert opinion is that it will take approximately 12 to 18 months to get one to market.
Related topics
Drug Development, Drug Discovery, Drug Leads, Drug Targets, Research & Development, Therapeutics, Vaccine
Related conditions
Coronary artery disease, Covid-19, Hepatitis, Influenza, Middle East respiratory syndrome coronavirus (MERS-CoV)
Related organisations
US Food and Drug Administration (FDA)
These drugs are already in use, so there should be enough data to show whether or not patients who are taking one of the drugs for other reasons are noticeably absent. When people are admitted to hospital, one of the first things determined is the medication they are on. Instant clinical trial. I’m sure this has already been done – has anyone published any results?
I agree that such retrospective data looks promising. The difficulty is, I think, in getting sufficiently large numbers of persons on such drugs and being able to compare them to a similar group to see if the drug group is doing better in some way.
If one is trying to look for improved outcomes, the fact that persons are taking drugs for other pre-existing health problems is a confounding factor. Plaquenil might be somewhat preventive for COVID-19, but in a person with lupus, the lupus condition itself may affect outcome.
So the analysis is more complicated, and requires larger numbers to arrive at results. But yes, this kind of data is potentially useful.